{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:05:46Z","timestamp":1740107146977,"version":"3.37.3"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00403-021-02262-7","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:14:51Z","timestamp":1624364091000},"page":"503-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review"],"prefix":"10.1007","volume":"314","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-0725","authenticated-orcid":false,"given":"Sahil","family":"Rawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Kianian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocellie","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Ayasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Siamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoojin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Salvemini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"5","key":"2262_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4103\/0019-5154.139859","volume":"59","author":"VN Sehgal","year":"2014","unstructured":"Sehgal VN, Pandhi D, Khurana A (2014) Biologics in dermatology: an integrated review. Indian J Dermatol 59(5):425\u2013441","journal-title":"Indian J Dermatol"},{"key":"2262_CR2","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Stelara 4508126 approval letter, October, 2019. from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761044s003lbl.pdf"},{"issue":"6","key":"2262_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ et al (2011) Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 3(6):535\u2013545","journal-title":"MAbs"},{"issue":"2","key":"2262_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2):133\u2013146","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"2262_CR5","doi-asserted-by":"publisher","first-page":"14002","DOI":"10.1073\/pnas.93.24.14002","volume":"93","author":"DH Presky","year":"1996","unstructured":"Presky DH, Yang H, Minetti LJ et al (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci 93(24):14002\u201314007","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"2262_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nbt.1903","volume":"29","author":"JM Benson","year":"2011","unstructured":"Benson JM, Sachs CW, Treacy G et al (2011) Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol 29(7):615\u2013624","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Tetzlaff J, Altman DG (2009) The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1468-3083.2010.03718_14.x","volume":"24","author":"M Bellutti","year":"2010","unstructured":"Bellutti M, Bonnekoh B, Gollnick H (2010) Pityriasis rubra pilaris of the adult type i resolved after monotherapy with ustekinumab. J Eur Acad Dermatol Venereol 24:72\u201372","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2262_CR9","first-page":"630","volume":"20","author":"R Ruiz Villaverde","year":"2010","unstructured":"Ruiz Villaverde R, Sanchez CD (2010) Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol 20(5):630\u2013631","journal-title":"Eur J Dermatol"},{"issue":"1","key":"2262_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3315\/jdcr.2010.1041","volume":"4","author":"M Slowinska","year":"2010","unstructured":"Slowinska M, Kardynal A, Warszawik O, Czuwara J, Rudnicka L (2010) Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep 4(1):15\u201317","journal-title":"J Dermatol Case Rep"},{"issue":"3","key":"2262_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2133.2010.09855.x","volume":"163","author":"J Wohlrab","year":"2010","unstructured":"Wohlrab J, Kreft B (2010) Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 163(3):655\u2013656","journal-title":"Br J Dermatol"},{"issue":"8","key":"2262_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/archdermatol.2011.185","volume":"147","author":"A De Souza","year":"2011","unstructured":"De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr (2011) Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 147(8):896\u2013898","journal-title":"Arch Dermatol"},{"issue":"4","key":"2262_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2012","unstructured":"Baerveldt EM, Kappen JH, Thio HB, van Laar JAM, van Hagen PM, Prens EP (2012) Successful long-term triple disease control by ustekinumab in a patient with Behcet\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 72(4):626\u2013627","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2262_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/ajg.2012.42","volume":"107","author":"M Fahmy","year":"2012","unstructured":"Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ (2012) Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 107(5):794\u2013795","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2262_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","volume":"26","author":"WP Gulliver","year":"2012","unstructured":"Gulliver WP, Jemec GB, Baker KA (2012) Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 26(7):911\u2013914","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2262_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-4632.2011.05195.x","volume":"51","author":"R Puya","year":"2012","unstructured":"Puya R, Alvarez-Lopez M, Velez A, Casas Asuncion E, Moreno JC (2012) Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 51(1):115\u2013116","journal-title":"Int J Dermatol"},{"issue":"3","key":"2262_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2340\/00015555-1229","volume":"92","author":"VR Sharon","year":"2012","unstructured":"Sharon VR, Garcia MS, Bagheri S et al (2012) Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 92(3):320\u2013321","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"2262_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D34G31C0TM","volume":"18","author":"C Verros","year":"2012","unstructured":"Verros C, Rallis E, Crowe M (2012) Letter: alopecia areata during ustekinumab administration: Co-existence or an adverse reaction? Dermatol Online J 18(7):14","journal-title":"Dermatol Online J"},{"issue":"9","key":"2262_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0961203312441982","volume":"21","author":"D Winchester","year":"2012","unstructured":"Winchester D, Duffin KC, Hansen C (2012) Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 21(9):1007\u20131010","journal-title":"Lupus"},{"issue":"3","key":"2262_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5021\/ad.2013.25.3.368","volume":"25","author":"A Agusti-Mejias","year":"2013","unstructured":"Agusti-Mejias A, Messeguer F, Garcia R, Febrer I (2013) Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 25(3):368\u2013370","journal-title":"Ann Dermatol"},{"issue":"20","key":"2262_CR21","first-page":"2831","volume":"17","author":"G Andrisani","year":"2013","unstructured":"Andrisani G, Marzo M, Celleno L et al (2013) Development of psoriasis scalp with alopecia during treatment of Crohn\u2019s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci 17(20):2831\u20132836","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"2262_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2340\/00015555-1467","volume":"93","author":"C Dahl","year":"2013","unstructured":"Dahl C, Johansen C, Kragballe K, Olesen AB (2013) Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol 93(3):368\u2013369","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"2262_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3315\/jdcr.2013.1127","volume":"7","author":"A Di Stefani","year":"2013","unstructured":"Di Stefani A, Galluzzo M, Talamonti M, Chiricozzi A, Costanzo A, Chimenti S (2013) Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. J Dermatol Case Rep 7(1):5\u20139","journal-title":"J Dermatol Case Rep"},{"issue":"4","key":"2262_CR24","first-page":"AB216","volume":"68","author":"S Fitz","year":"2013","unstructured":"Fitz S, Longley BJ, Puchalsky D (2013) Treatment of pityriasis rubra pilaris with ustekinumab. J Am Acad Dermatol 68(4):AB216","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2262_CR25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bjd.12163","volume":"168","author":"Y Majima","year":"2013","unstructured":"Majima Y, Yagi H, Tateishi C et al (2013) A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis. Br J Dermatol 168(6):1367\u20131369","journal-title":"Br J Dermatol"},{"issue":"2","key":"2262_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bjd.12952","volume":"171","author":"O Eytan","year":"2014","unstructured":"Eytan O, Sarig O, Sprecher E, van Steensel MAM (2014) Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol 171(2):420\u2013422","journal-title":"Br J Dermatol"},{"issue":"3","key":"2262_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ad.2013.05.003","volume":"105","author":"MC Fernandez-Anton Martinez","year":"2014","unstructured":"Fernandez-Anton Martinez MC, Alfageme Roldan F, Ciudad Blanco C, Suarez FR (2014) Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 105(3):312\u2013313","journal-title":"Actas Dermosifiliogr"},{"key":"2262_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"SH Foo","year":"2014","unstructured":"Foo SH, Rowe A, Maheshwari MB, Abdullah A (2014) The challenge of managing pityriasis rubra pilaris: success at last with ustekinumab? Br J Dermatol 171:155\u2013155","journal-title":"Br J Dermatol"},{"issue":"7","key":"2262_CR29","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","volume":"105","author":"MI Santos-Perez","year":"2014","unstructured":"Santos-Perez MI, Garcia-Rodicio S, Del Olmo-Revuelto MA, Pozo-Roman T (2014) Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr 105(7):720\u2013722","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"2262_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000381011","volume":"7","author":"M Chowdhary","year":"2015","unstructured":"Chowdhary M, Davila U, Cohen DJ (2015) Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris. Case Rep Dermatol 7(1):46\u201350","journal-title":"Case Rep Dermatol"},{"issue":"6","key":"2262_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2015.07.014","volume":"1","author":"A Le Guern","year":"2015","unstructured":"Le Guern A, Alkeraye S, Vermersch-Langlin A, Coupe P, Vonarx M (2015) Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep 1(6):359\u2013360","journal-title":"JAAD Case Rep"},{"issue":"3","key":"2262_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/2229-5178.156410","volume":"6","author":"VD Lernia","year":"2015","unstructured":"Lernia VD, Ficarelli E, Zanelli M (2015) Ineffectiveness of tumor necrosis factor-alpha blockers and ustekinumab in a case of type IV pityriasis rubra pilaris. Indian Dermatol Online J 6(3):207\u2013209","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"2262_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.alit.2015.06.003","volume":"64","author":"A Lis-wi\u0119ty","year":"2015","unstructured":"Lis-wi\u0119ty A, Skrzypek-Salamon A, Arasiewicz H, Brzezi\u0144ska-Wcis\u0142o L (2015) Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int 64(4):382\u2013383","journal-title":"Allergol Int"},{"issue":"1","key":"2262_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jdv.12438","volume":"29","author":"G Martin-Ezquerra","year":"2015","unstructured":"Martin-Ezquerra G, Masferrer E, Masferrer-Niubo M et al (2015) Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(1):56\u201360","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"2262_CR35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/1346-8138.12943","volume":"42","author":"C Nakayama","year":"2015","unstructured":"Nakayama C, Fujita Y, Watanabe M, Shimizu H (2015) Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol 42(10):996\u2013998","journal-title":"J Dermatol"},{"issue":"1","key":"2262_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jdcr.2014.10.007","volume":"1","author":"A Shroff","year":"2015","unstructured":"Shroff A, Guttman-Yassky E (2015) Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep 1(1):25\u201326","journal-title":"JAAD Case Rep"},{"issue":"11","key":"2262_CR37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5070\/D32111029305","volume":"21","author":"G Webster","year":"2015","unstructured":"Webster G (2015) Failure of lichen planopilaris to respond to ustekinumab. Dermatol Online J 21(11):17","journal-title":"Dermatol Online J"},{"issue":"4","key":"2262_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","volume":"174","author":"JL Blok","year":"2016","unstructured":"Blok JL, Li K, Brodmerkel C, Horvatovich P, Jonkman MF, Horvath B (2016) Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 174(4):839\u2013846","journal-title":"Br J Dermatol"},{"issue":"5","key":"2262_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/iwj.12377","volume":"13","author":"I Cosgarea","year":"2016","unstructured":"Cosgarea I, Lovric Z, Korber A, Dissemond J (2016) Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J 13(5):1041\u20131042","journal-title":"Int Wound J"},{"issue":"6","key":"2262_CR40","first-page":"S188","volume":"34","author":"L Costa","year":"2016","unstructured":"Costa L, Del Puente A, Foglia F et al (2016) Ustekinumab efficacy in refractory Behcet\u2019s disease. Clin Exp Rheumatol 34(6):S188\u2013S188","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2262_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bcp.12837","volume":"81","author":"C Guarneri","year":"2016","unstructured":"Guarneri C, Lentini M, Polimeni G, Giuffrida R, Cannavo SP (2016) Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Br J Clin Pharmacol 81(4):792\u2013794","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2262_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","volume":"137","author":"E Guttman-Yassky","year":"2016","unstructured":"Guttman-Yassky E, Ungar B, Noda S et al (2016) Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism. Journal of Allergy and Clinical Immunology 137(1):301\u2013304","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"2262_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jdv.12918","volume":"30","author":"LP Samorano","year":"2016","unstructured":"Samorano LP, Hanifin JM, Simpson EL, Leshem YA (2016) Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol 30(3):522\u2013523","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2262_CR44","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1111\/ajd.12545","volume":"58","author":"M Benzaquen","year":"2017","unstructured":"Benzaquen M, Monnier J, Beaussault Y, Rouby F, Berbis P (2017) Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol 58(4):e270\u2013e271","journal-title":"Australas J Dermatol"},{"issue":"6","key":"2262_CR45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jdcr.2017.07.009","volume":"3","author":"A Elkady","year":"2017","unstructured":"Elkady A, Bonomo L, Amir Y, Vekaria AS, Guttman-Yassky E (2017) Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata. JAAD case reports 3(6):477\u2013479","journal-title":"JAAD case reports"},{"issue":"1","key":"2262_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/exd.13112","volume":"26","author":"S Khattri","year":"2017","unstructured":"Khattri S, Brunner PM, Garcet S et al (2017) Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 26(1):28\u201335","journal-title":"Exp Dermatol"},{"issue":"6","key":"2262_CR47","doi-asserted-by":"publisher","first-page":"e12559","DOI":"10.1111\/dth.12559","volume":"30","author":"NJ Maloney","year":"2017","unstructured":"Maloney NJ, Hisaw LD, Worswick S (2017) Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation. Dermatol Ther 30(6):e12559","journal-title":"Dermatol Ther"},{"issue":"1","key":"2262_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/jdv.13759","volume":"31","author":"L Mery-Bossard","year":"2017","unstructured":"Mery-Bossard L, Bagny K, Chaby G et al (2017) New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol 31(1):181\u2013186","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2262_CR49","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/bjd.15262","volume":"177","author":"E Nic Dhonncha","year":"2017","unstructured":"Nic Dhonncha E, Clowry J, Dunphy M, Buckley C, Field S, Paul L (2017) Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients. Br J Dermatol 177(6):1752\u20131753","journal-title":"Br J Dermatol"},{"issue":"1","key":"2262_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1684\/ejd.2016.2888","volume":"27","author":"N Onsun","year":"2017","unstructured":"Onsun N, Sallahoglu K, Dizman D, Su O, Tosuner Z (2017) Bullous pemphigoid during ustekinumab therapy in a psoriatic patient. Eur J Dermatol 27(1):81\u201382","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2262_CR51","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1111\/jdv.14009","volume":"31","author":"A Paganelli","year":"2017","unstructured":"Paganelli A, Ciardo S, Odorici G, Pellacani G, Conti A (2017) Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT). J Eur Acad Dermatol Venereol 31(5):e249\u2013e251","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2262_CR52","doi-asserted-by":"publisher","DOI":"10.5070\/D3231033677","author":"A Romero-Mate","year":"2017","unstructured":"Romero-Mate A, Garcia-Donoso C, Hernandez-Nunez A, Martinez-Moran C, Moreno-Torres A, Borbujo-Martinez J (2017) Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab. Dermatol Online J. https:\/\/doi.org\/10.5070\/D3231033677","journal-title":"Dermatol Online J"},{"issue":"2","key":"2262_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.15493","volume":"177","author":"H Saeki","year":"2017","unstructured":"Saeki H, Kabashima K, Tokura Y et al (2017) Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 177(2):419\u2013427","journal-title":"Br J Dermatol"},{"issue":"1","key":"2262_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2016.07.047","volume":"76","author":"D Weiss","year":"2017","unstructured":"Weiss D, Schaschinger M, Ristl R et al (2017) Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2\/22 expression. J Am Acad Dermatol 76(1):91-97.e93","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2262_CR55","first-page":"1022","volume":"16","author":"R Aragon-Miguel","year":"2018","unstructured":"Aragon-Miguel R, Prieto-Barrios M, Calleja-Algarra A et al (2018) Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. J Dtsch Dermatol Ges 16(8):1022\u20131025","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"2262_CR56","first-page":"AB24","volume":"79","author":"C Collantes-Rodriguez","year":"2018","unstructured":"Collantes-Rodriguez C, Ossorio-Garcia L, Villegas-Romero I et al (2018) A single case of hidradenitis suppurativa, Crohn\u2019s disease, and psoriasis treated with ustekinumab. J Am Acad Dermatol 79(3):AB24","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2262_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","volume":"79","author":"BG Craiglow","year":"2018","unstructured":"Craiglow BG, Boyden LM, Hu R et al (2018) CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol 79(3):487\u2013494","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2262_CR58","doi-asserted-by":"publisher","first-page":"e12742","DOI":"10.1111\/dth.12742","volume":"31","author":"MA Gkini","year":"2018","unstructured":"Gkini MA, Bewley AP (2018) Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction? Dermatol Ther 31(6):e12742","journal-title":"Dermatol Ther"},{"key":"2262_CR59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.16859","volume":"179","author":"E Horton","year":"2018","unstructured":"Horton E, Ghumra W, El-Mansori I, Layton A, Eady A, Lee N (2018) Curse or cure: paradoxical side-effects of biological agents. Br J Dermatol 179:68","journal-title":"Br J Dermatol"},{"issue":"6","key":"2262_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.14295","volume":"45","author":"Y Ishiuji","year":"2018","unstructured":"Ishiuji Y, Umezawa Y, Asahina A et al (2018) Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol 45(6):732\u2013734","journal-title":"J Dermatol"},{"issue":"6","key":"2262_CR61","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/ced.13626","volume":"43","author":"N Ismail","year":"2018","unstructured":"Ismail N, Callander J, Williams M, Anstey AV (2018) Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab. Clin Exp Dermatol 43(6):749\u2013751","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"2262_CR62","first-page":"AB205","volume":"79","author":"SR Kim","year":"2018","unstructured":"Kim SR, Liu L, King B (2018) No hair regrowth in three patients with alopecia universalis treated with ustekinumab. J Am Acad Dermatol 79(3):AB205","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2262_CR63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.15462","volume":"178","author":"SM Lwin","year":"2018","unstructured":"Lwin SM, Hsu CK, Liu L, Huang HY, Levell NJ, McGrath JA (2018) Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol 178(4):969\u2013972","journal-title":"Br J Dermatol"},{"issue":"3","key":"2262_CR64","first-page":"AB309","volume":"79","author":"F Moreno-Suarez","year":"2018","unstructured":"Moreno-Suarez F, Del Carmen S-N, Aceituno-Madera P, Ramos-Pleguezuelos FM (2018) Ustekinumab an alternative therapeutic option for refractory erytroderma pytiriasis rubra pilaris disease. J Am Acad Dermatol 79(3):AB309","journal-title":"J Am Acad Dermatol"},{"key":"2262_CR65","unstructured":"Moretta G, Caldarola G, Potenza A, Peris K, De Simone C. A case of chronic disseminated lupus erythematous in a psoriatic patient receiving ustekinumab. G Ital Dermatol Venereol. 2018."},{"issue":"2","key":"2262_CR66","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/1346-8138.14114","volume":"45","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B (2018) Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases. J Dermatol 45(2):202\u2013206","journal-title":"J Dermatol"},{"issue":"1","key":"2262_CR67","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1111\/pde.13699","volume":"36","author":"A Aleisa","year":"2019","unstructured":"Aleisa A, Lim Y, Gordon S et al (2019) Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol 36(1):e44\u2013e45","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2262_CR68","first-page":"AB293","volume":"81","author":"JJ Andres-Lencina","year":"2019","unstructured":"Andres-Lencina JJ, Arag\u00f3n-Miguel R, Calleja-Algarra A et al (2019) Ultrasound, surgery, and ustekinumab: a perfect triangle for hidradenitis suppurativa. J Am Acad Dermatol 81(4):AB293","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2262_CR69","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/1346-8138.14816","volume":"46","author":"K Ezzedine","year":"2019","unstructured":"Ezzedine K, Visseaux L, Cadiot G, Brixi H, Bernard P, Reguiai Z (2019) Ustekinumab for skin reactions associated with anti-tumor necrosis factor-alpha agents in patients with inflammatory bowel diseases: a single-center retrospective study. J Dermatol 46(4):322\u2013327","journal-title":"J Dermatol"},{"issue":"8","key":"2262_CR70","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.medcli.2018.12.004","volume":"153","author":"P Garcia Camara","year":"2019","unstructured":"Garcia Camara P, Zubiri Ara ML, Garcia LS (2019) Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn\u2019s disease. Med Clin 153(8):e35\u2013e36","journal-title":"Med Clin"},{"key":"2262_CR71","doi-asserted-by":"publisher","DOI":"10.5070\/D3257044808","author":"AD King","year":"2019","unstructured":"King AD, Lam L, Goh C (2019) Onset of frontal fibrosing alopecia during inhibition of Th1\/17 Pathways with ustekinumab. Dermatol Online J. https:\/\/doi.org\/10.5070\/D3257044808","journal-title":"Dermatol Online J"},{"issue":"1","key":"2262_CR72","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1346-8138.14709","volume":"46","author":"T Matsuda","year":"2019","unstructured":"Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H (2019) Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40. J Dermatol 46(1):70\u201372","journal-title":"J Dermatol"},{"issue":"1","key":"2262_CR73","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/ced.13679","volume":"44","author":"D Nieto","year":"2019","unstructured":"Nieto D, Sendagorta E, Rueda JM, Herranz P (2019) Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. Clin Exp Dermatol 44(1):116\u2013119","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2262_CR74","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/ecco-jcc\/jjy200","volume":"13","author":"G Nunes","year":"2019","unstructured":"Nunes G, Patita M, Fernandes V (2019) Refractory pyoderma gangrenosum in a patient with Crohn\u2019s disease: complete response to ustekinumab. J Crohns Colitis 13(6):812\u2013813","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2262_CR75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1684\/ejd.2019.3663","volume":"29","author":"L Scholl","year":"2019","unstructured":"Scholl L, Hessam S, Garcovich S, Bechara FG (2019) High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Eur J Dermatol 29(6):659\u2013661","journal-title":"Eur J Dermatol"},{"key":"2262_CR76","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","volume":"10","author":"F Solimani","year":"2019","unstructured":"Solimani F, Pollmann R, Schmidt T et al (2019) Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol 10:1808","journal-title":"Front Immunol"},{"issue":"3","key":"2262_CR77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jdcr.2019.01.015","volume":"5","author":"E Tierney","year":"2019","unstructured":"Tierney E, Kirthi S, Ramsay B, Ahmad K (2019) Ustekinumab-induced subacute cutaneous lupus. JAAD Case Rep 5(3):271\u2013273","journal-title":"JAAD Case Rep"},{"issue":"1","key":"2262_CR78","first-page":"32","volume":"53","author":"S Vural","year":"2019","unstructured":"Vural S, Gundogdu M, Ertop P et al (2019) Ustekinumab associated bullous pemphigoid in a psoriasis patient and a review of the literature. Turkderm-Turkish Arch Dermatol Venerol 53(1):32\u201335","journal-title":"Turkderm-Turkish Arch Dermatol Venerol"},{"issue":"2","key":"2262_CR79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1574886315666200316113312","volume":"15","author":"S Kobak","year":"2020","unstructured":"Kobak S, Semiz H (2020) Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis. Curr Drug Saf 15(2):163\u2013166","journal-title":"Curr Drug Saf"},{"key":"2262_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1755008","author":"T Montero-Vilchez","year":"2020","unstructured":"Montero-Vilchez T, Pozo-Roman T, Sanchez-Velicia L, Vega-Gutierrez J, Arias-Santiago S, Molina-Leyva A (2020) Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2020.1755008","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"2262_CR81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000501075","volume":"236","author":"J Romani","year":"2020","unstructured":"Romani J, Vilarrasa E, Martorell A, Fuertes I, Ciudad C, Molina-Leyva A (2020) Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology 236(1):21\u201324","journal-title":"Dermatology"},{"key":"2262_CR82","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1136\/lupus-2018-000288","volume":"5","author":"R Van Vollenhoven","year":"2018","unstructured":"Van Vollenhoven R, Hahn B, Tsokos G et al (2018) Efficacy and safety of ustekinumab, an interleukin 12\/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. Lupus Sci Med 5:A28\u2013A29","journal-title":"Lupus Sci Med"},{"key":"2262_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/art.41179","author":"RF van Vollenhoven","year":"2019","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC et al (2019) Maintenance of efficacy and safety of ustekinumab through one year in a phase ii multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41179","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2262_CR84","first-page":"32","volume":"17","author":"K Herberger","year":"2019","unstructured":"Herberger K, Dissemond J, Br\u00fcggestrat S, Sorbe C, Augustin M (2019) Biologics and immunoglobulins in the treatment of pyoderma gangrenosum\u2014analysis of 52 patients. JDDG 17(1):32\u201341","journal-title":"JDDG"},{"key":"2262_CR85","unstructured":"NCT (2009) A study to evaluate the safety and effectiveness of ustekinumab or golimumab administered subcutaneously (SC) in patients with sarcoidosis https:\/\/clinicaltrials.gov\/show\/NCT00955279"},{"key":"2262_CR86","unstructured":"NCT (2013a) A study of ustekinumab (STELARA\u00ae) in adult Japanese participants with severe atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT01945086"},{"key":"2262_CR87","unstructured":"NCT (2013b) Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis https:\/\/clinicaltrials.gov\/show\/NCT01806662"},{"key":"2262_CR88","unstructured":"NCT (2015) A phase 2a, efficacy and safety study of ustekinumab in systemic lupus erythematosus https:\/\/clinicaltrials.gov\/show\/NCT02349061"},{"key":"2262_CR89","unstructured":"NCT (2018) A study of ustekinumab in participants with active systemic lupus erythematosus https:\/\/clinicaltrials.gov\/show\/NCT03517722"},{"key":"2262_CR90","unstructured":"NCT (2019) A study of ustekinumab in chinese participants with active systemic lupus erythematosus https:\/\/clinicaltrials.gov\/show\/NCT04060888"},{"key":"2262_CR91","unstructured":"Euctr DE (2009) A phase 2, multicenter, randomized, double blind, parallel group, placebo controlled study evaluating the safety and efficacy of treatment with ustekinumab or golimumab in subjects with chronic sarcoidosis http:\/\/www.whoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2009-010714-30-DE"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02262-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T04:47:24Z","timestamp":1672548444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02262-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02262-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sahil Rawal, Sara Kianian, William Guo, Jocellie Marquez, Marissa Ayasse, Katherine A. Siamas, Yoojin Lee, and Joann Salvemini report no conflicts of interest or competing interests that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain studies on human or animal subjects that require approval by an ethics board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not discuss any individuals or material that would require consent for participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This article does not discuss any individuals or material that would require consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}